A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

Podobne knjige/članki

• Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
  od: Giatromanolaki, A, et al.
  Izdano: (2012)
• Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
  od: Koukourakis, M, et al.
  Izdano: (2011)
• Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
  od: Hecht, JR, et al.
  Izdano: (2011)
• A phase II study of PTK787 in metastatic melanoma patients
  od: Corrie, P, et al.
  Izdano: (2008)
• Design and Exercise of Flexibility in the Boeing 787 Dreamliner
  od: McConnell, Joshua
  Izdano: (2013)